Key Highlights

  • Clarity Pharmaceuticals shares were trading at $1.88 during the 13 November 2026 session, down 8.42%.
  • The FDA granted Breakthrough Therapy Designation for PET imaging of PSMA-positive lesions with Cu-64 SAR-bisPSMA, announced on 12 November 2026.
  • Topline data from the Phase III AMPLIFY and CLARIFY trials are expected in the first half of calendar 2027.

During the Trading session on 13 November 2026, Clarity Pharmaceuticals Ltd (ASX:CU6) shares were trading at $1.88, down 8.42%, while the S&P/ASX 200 was down 0.73% at 9,079.70 at 12:39 pm AEDT. Clarity is a clinical-stage radiopharmaceutical company developing Targeted Copper Theranostics based on its SAR technology platform. Its latest update, dated 12 November 2026, announced a regulatory designation for its lead diagnostic product.

FDA Breakthrough Therapy designation

The United States Food and Drug Administration granted Breakthrough Therapy designation for positron emission tomography imaging of PSMA-positive lesions with Cu-64 SAR-bisPSMA in men with prostate cancer and suspected recurrence based on elevated PSA. Clarity described it as the first such designation for PSMA PET imaging. The designation is intended to expedite development and review, and can make a product eligible for priority review when a new drug application is filed.

Supporting clinical data

The designation was supported by the Phase II Co-PSMA trial, the Phase I/II COBRA trial and real-world evidence. In Co-PSMA, the company said the detection rate for Cu-64 SAR-bisPSMA was 78% in the same patient group, compared with 36% for Ga-68 PSMA-11. In COBRA, next-day imaging detected lesions in a higher proportion of patients than the standard-of-care scans, and management changes were reported in about 44% of patients in Co-PSMA.

Phase III program

Clarity is running two registrational Phase III trials, AMPLIFY and CLARIFY, both of which have completed recruitment and are in patient follow-up. Topline data from both trials are expected in the first half of calendar 2027. The company intends the final results to support an application to the FDA for approval of Cu-64 SAR-bisPSMA as a diagnostic imaging agent.

Sector context

PSMA PET imaging has grown into a substantial market, with the company citing US sales of around US$2 billion a year, expected to exceed US$3 billion by 2029. Companies in the field compete on detection rates and on the convenience of supply, and new agents must show improved performance over approved products to gain adoption.

Risks investors are watching

The product is unregistered, and its safety and efficacy have not been assessed by the FDA or the Therapeutic Goods Administration. The designation does not guarantee approval, and the company notes that fewer than half of designation requests are successful. Phase III topline results are not yet available, and the company's detection claims rely on trial data that will be finalised later. Commercial availability is not guaranteed.

What to watch ahead

Investors will look for the topline results from AMPLIFY and CLARIFY in the first half of 2027, and any update on the timing of an FDA application. The company's future announcements on the program's progress will also be followed.

Final Word

Clarity's latest announcement adds a Breakthrough Therapy designation to its PSMA imaging program, with pivotal trial data still to come. The Phase III results will determine whether the designation translates into regulatory approval.